JPMorgan Chase & Co. Has $38.64 Million Holdings in Elanco Animal Health Incorporated $ELAN

JPMorgan Chase & Co. raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 266.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,918,336 shares of the company’s stock after purchasing an additional 1,394,839 shares during the period. JPMorgan Chase & Co. owned 0.39% of Elanco Animal Health worth $38,635,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. SJS Investment Consulting Inc. raised its stake in Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the last quarter. Huntington National Bank grew its holdings in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after acquiring an additional 900 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in shares of Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after purchasing an additional 2,807 shares during the period. 97.48% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ELAN has been the subject of several recent analyst reports. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. KeyCorp increased their price target on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Stock Down 4.5%

Shares of NYSE:ELAN opened at $23.98 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72. The business’s 50 day simple moving average is $24.65 and its two-hundred day simple moving average is $22.44. The firm has a market cap of $11.92 billion, a P/E ratio of -49.95, a PEG ratio of 3.05 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.